This year's keynote speaker is Daniel Ammon, PhD, Vice President of R&D at Regenity Biosciences in Paramus, NJ. Dr. Ammon will be presenting on Regenity’s biomaterial portfolio, including a new meniscus replacement device. He previously served as President of the Surfaces in Biomaterials Foundation from 2004-2005. His impressive track record of taking products from concept to launch includes dozens of medical devices in use today.

Dr. Ammon will be presenting on Regenity’s biomaterial portfolio, including a new meniscus replacement device. Dr. Ammon's abstract is as follows:

The standard of care for a moderate meniscal tear is a meniscectomy. While the short-term prognosis is positive, long-term complications like osteoarthritis are likely. Regenity Biosciences has engineered a collagen scaffold for the repair and regeneration of the human meniscus.  The meniscal implant should solve the clinical issues that are observed as a result of today’s standard of care. The presentation will review the clinical needs, the meniscal implant device, a pilot study and a pivotal study. The objective of these studies was to evaluate the ability of the Test Article, Collagen Meniscus Implant (CMI), to support host meniscal tissue regeneration and repair when implanted into a subtotal medial meniscectomized (approximately 80%) canine knee. The pivotal study demonstrated that CMI Implants were safe, biocompatible and associated with meniscus defect tissue repair and remodeling that is superior to the empty defect (partial
meniscectomy) and not significantly different from fresh frozen allograft implants, in the treatment of remnant, red-red zone, medial meniscal tissue with an intact rim and roots, resulting from an 80% of the surface area medial meniscal defect creation, based on the 3, 6, 9 and 12 month functional, gross, histologic, biomechanical and biochemical measures in this preclinical canine model.